Latest Lead News

EVE Health Group has completed its acquisition of Nextract, raised $1 million to fund manufacturing, and achieved key regulatory and commercial milestones for its pharmaceutical products targeting erectile dysfunction and dysmenorrhea.

iTech Minerals has significantly extended the strike length of gold-antimony mineralisation at its Reynolds Range Project, revealing new high-priority drill targets and advancing its lithium deal with SQM.

Odessa Minerals reports encouraging base metal anomalies and uranium exploration progress at its Lyndon Project, alongside strategic board changes and ongoing acquisition reviews.

Australian Vanadium Limited (AVL) reports strong progress on its integrated vanadium project, moving closer to final feasibility and advancing its utility-scale battery storage system, Project Lumina.

Osteopore Limited has posted a record AUD 835K revenue in Q2 CY25, driven by strong APAC sales and new European market access following EU MDR clearance. The company also advances clinical trials and refreshes key distribution channels.

TrivarX has secured key approvals and begun recruiting for its innovative mental health screening trial in US veterans, while also launching a wearable tech pilot with a Major League Baseball academy in the Dominican Republic.

American Rare Earths Limited reports strong progress at its Halleck Creek Rare Earths Project, highlighted by exceptional sampling results, key permitting milestones, and a $15 million equity raise to fund development.

Neurotech International reports encouraging Phase I human pharmacokinetic results for its pediatric cannabinoid drug NTI164, alongside published clinical trial data in Rett Syndrome and key regulatory progress in the US and Australia.

TechGen Metals Limited has announced a fully underwritten $2.57 million rights issue to accelerate exploration and drilling at its Blue Devil and Mt Boggola copper-gold projects in Western Australia.

FlexiRoam Limited has achieved profitability in Q4 FY25, marking a significant turnaround with a positive EBITDA and net profit. Founder Jefrey Ong is appointed permanent CEO to steer the company’s next growth phase.

Golden Mile Resources has completed its first Reverse Circulation drilling campaign at the Pearl Copper Project in Arizona, revealing significant copper, lead, zinc, and silver mineralisation. Meanwhile, drilling continues at its Leonora Gold JV with assay results pending.

Amplia Therapeutics reports encouraging ACCENT trial results for its FAK inhibitor narmafotinib, including rare complete responses in pancreatic cancer, alongside a $27.5 million capital raise to fund ongoing clinical development.